RxDoctor Payments Data

Nemi Shah

Urogynecology and Reconstructive Pelvic Surgery · Murrieta, CANPI 1558715268

Payments from drug & device makers

$2,704in general payments, 2019–2025

Across 76 payments — averaging $35.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$820
  • Coloplast$241
  • Procept Biorobotics Corporation$217
  • Sumitomo Pharma America, Inc.$201
  • Boston Scientific$197
  • Medtronic$162
  • plus $865 from 23 others

What the payments were for

  • Travel & lodging$38914%
  • Food & beverage$2,09878%
  • Education$2168%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,704 in reported general payments places this provider in the 35th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$175,643
Medicare patients
258
Services billed
3,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron172$125,202
MyrbetriqMirabegron158$100,328
Estradiol345$19,856
EstringEstradiol32$17,661
Trospium Chloride ErTrospium Chloride63$10,328
Methenamine Hippurate142$10,032
YuvafemEstradiol80$6,851
Trospium Chloride139$5,090
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst217$2,259
Clobetasol Propionate61$2,197
Cefpodoxime Proxetil18$1,536
Estradiol (Once Weekly)Estradiol31$1,294
Ibuprofen88$490
Metronidazole30$364
Ondansetron OdtOndansetron72$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$201$125,202172 claims
Astellas Pharma US IncMyrbetriq$85$100,328158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

Other urogynecology and reconstructive pelvic surgery in Murrieta

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →